Supporting information for

Systems analysis of plasma IgG intact N-glycopeptides from patients with chronic kidney diseases via EThcD-sceHCD-MS/MS

Yong Zhang[1, 2*], Shanshan Zheng[1], Yonghong Mao[3], Wei Cao[1], Lijun Zhao[4], Changwei Wu[5], Jingqiu Cheng[1], Fang Liu[4,*], Guisen Li[5,*], Hao Yang[1, 2*]

[1]NHC Key Laboratory of Transplant Engineering and Immunology, Institutes for Systems Genetics; National Clinical Research Center for Geriatrics，West China Hospital, Sichuan University, Chengdu 610041, China.

[2]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University, Chengdu 610041, China.

[3]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.

[4]Division of Nephrology, West China Hospital, Sichuan University, Chengdu, 610041, China.

[5]Renal Department and Institute of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu 611731, China.

*Corresponding authors.

E-mail address: nankai1989@foxmail.com (Y. Zhang), liufangfh@163.com (F. Liu), guisenli@163.com (GS. Li), yanghao@scu.edu.cn (H. Yang)

Supplementary Figures:

Figure S1. The relative abundance of IgG subclasses (A) and the number of unique intact N-glycopeptides and N-glycans (B) of qual-ity control (QC) samples;

Figure S2. Correlation analysis of eight quality control (QC) samples;

Figure S3. Comparison of the average number of IgG intact N-glycopeptides and N-glycans (A), and the positive rate of intact N-glycopeptides from IgG1 (B), IgG2 (C), IgG3 (D) and IgG4 (E) between HC, MN, DKD and IgAN group ("*" means P<0.05, ** means P<0.005);

Figure S4. Comparison of the relative abundance of IgG subclasses between HC, MN, DKD and IgAN group;

(XLSX) Table S1. Relative abundance of IgG subclasses and the number of unique intact N-glycopeptides and N-glycans of quality control samples;

(XLSX) Table S2. Clinical de-mographics of HC, MN, DKD and IgAN groups;

(XLSX) Table S3. Positive rate of identified IgG intact N-glycopeptides from HC, MN, DKD and IgAN groups;

(XLSX) Table S4. Differentially expressed intact N-glycopeptides of human plasma IgGs from HC, MN, DKD and IgAN groups.

Figure S1. The relative abundance of IgG subclasses (A) and the number of unique intact N-glycopeptides and N-glycans (B) of quality control (QC) samples

A

B

Figure S2. Correlation analysis of eight quality control (QC) samples

Figure S3. Comparison of the average number of IgG intact N-glycopeptides and N-glycans (A), and the positive rate of intact N-glycopeptides from IgG1 (B), IgG2 (C), IgG3 (D) and IgG4 (E) between HC, MN, DKD and IgAN group (* means *P*<0.05, ** means *P*<0.005).

Figure S4. Comparison of the relative abundance of IgG subclasses between HC, MN, DKD and IgAN group.